Adverse events415

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 415

Type	Event	Organ system	Group	Affected	At risk
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	DL1 (Ixazomib 2.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	2	3
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	DL2 (Ixazomib 3.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	2	3
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	DL3/MTD (Ixazomib 4.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	2	6
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	Expansion Cohort I: Follicular Lymphoma at MTD	5	6
other	Rash maculo-papular	Skin and subcutaneous tissue disorders	Expansion Cohort 2: Non-Follicular Lymphoma at MTD		0
other	Rash acneiform	Skin and subcutaneous tissue disorders	DL1 (Ixazomib 2.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	3
other	Rash acneiform	Skin and subcutaneous tissue disorders	DL2 (Ixazomib 3.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	1	3
other	Rash acneiform	Skin and subcutaneous tissue disorders	DL3/MTD (Ixazomib 4.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	1	6
other	Rash acneiform	Skin and subcutaneous tissue disorders	Expansion Cohort I: Follicular Lymphoma at MTD	0	6
other	Rash acneiform	Skin and subcutaneous tissue disorders	Expansion Cohort 2: Non-Follicular Lymphoma at MTD		0
other	Basal cell carcinoma	Skin and subcutaneous tissue disorders	DL1 (Ixazomib 2.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	3
other	Basal cell carcinoma	Skin and subcutaneous tissue disorders	DL2 (Ixazomib 3.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	3
other	Basal cell carcinoma	Skin and subcutaneous tissue disorders	DL3/MTD (Ixazomib 4.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	6
other	Basal cell carcinoma	Skin and subcutaneous tissue disorders	Expansion Cohort I: Follicular Lymphoma at MTD	1	6
other	Basal cell carcinoma	Skin and subcutaneous tissue disorders	Expansion Cohort 2: Non-Follicular Lymphoma at MTD		0
other	Indeterminate skin eruptions	Skin and subcutaneous tissue disorders	DL1 (Ixazomib 2.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	3
other	Indeterminate skin eruptions	Skin and subcutaneous tissue disorders	DL2 (Ixazomib 3.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	3
other	Indeterminate skin eruptions	Skin and subcutaneous tissue disorders	DL3/MTD (Ixazomib 4.0 mg + Lenalidomide 20 mg + Rituximab 375mg/m2)	0	6
other	Indeterminate skin eruptions	Skin and subcutaneous tissue disorders	Expansion Cohort I: Follicular Lymphoma at MTD	1	6
other	Indeterminate skin eruptions	Skin and subcutaneous tissue disorders	Expansion Cohort 2: Non-Follicular Lymphoma at MTD		0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02898259/events

API reference For AI assistants

Adverse events415

Sources 3

Read this list from software.